247 results on '"Lee, Man Po"'
Search Results
2. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial
- Author
-
Avihingsanon, Anchalee, Lu, Hongzhou, Leong, Chee Loon, Hung, Chien-Ching, Koenig, Ellen, Kiertiburanakul, Sasisopin, Lee, Man-Po, Supparatpinyo, Khuanchai, Zhang, Fujie, Rahman, Sophia, D'Antoni, Michelle L, Wang, Hongyuan, Hindman, Jason T, Martin, Hal, Baeten, Jared M, and Li, Taisheng
- Published
- 2023
- Full Text
- View/download PDF
3. Prevalence and Risks of Depression and Substance Use Among Adults Living with HIV in the Asia–Pacific Region
- Author
-
Ross, Jeremy L., Jiamsakul, Awachana, Avihingsanon, Anchalee, Lee, Man Po, Ditangco, Rossana, Choi, Jun Yong, Rajasuriar, Reena, Gatechompol, Sivaporn, Chan, Iris, Melgar, Maria Isabel Echanis, Kim, Jung Ho, Chong, Meng Li, Sohn, Annette H., and Law, Matthew
- Published
- 2022
- Full Text
- View/download PDF
4. Implementation of “Treat‐all” at adult HIV care and treatment sites in the Global IeDEA Consortium: results from the Site Assessment Survey
- Author
-
Brazier, Ellen, Maruri, Fernanda, Duda, Stephany N, Tymejczyk, Olga, Wester, C William, Somi, Geoffrey, Ross, Jeremy, Freeman, Aimee, Cornell, Morna, Poda, Armel, Musick, Beverly S, Zhang, Fujie, Althoff, Keri N, Mugglin, Catrina, Kimmel, April D, Yotebieng, Marcel, Nash, Denis, Karminia, Azar, Sohn, Annette H, Allen, Debbie, Bloch, Mark, Boyd, Susan, Brown, Katherine, Costa, Jess, Donohue, William, Gunathilake, Manoji, Hoy, Jennifer, MacRae, Karen, Moore, Richard, Roth, Norman, Rowling, Diane, Silvers, Julie, Smith, Sowden, David, Templeton, David, Varma, Rick, Woolley, Ian, Youds, David, Meng, Somanithd Chhay, Vannary, Bun, Chan, Yun Ting, Lam, Wilson, Lee, Man Po, Ning, Han, Pansy, Yu Po Chu, Kumarasamy, N, Pujari, Sanjay, Kurniati, Nia, Merati, Tuti Parwati, Muktiarti, Dina, Parwata, Wayan Sandhi, Ratni, Made, Sukmawati, Ni Made Dewi Dian, Vedaswari, Dian Sulistya Putu Diah, Wati, Ketut Dewi Kumara, Yunihastuty, Evy, Tanuma, Junko, Mills, Graham, Raymond, Nigel, Ditangco, Rossana, Papa, Ohnmar Seinn, Tek, Ng Oon, Ah‐neez, Azwa, Raja, Dato, Daud, Fauziah, Juin, Wong Ke, Kamarulzaman, Adeeba Binti, Khairulddin, Nik, Li, Chong Meng, Moy, Fong Siew, Shah, Raja Iskandar, Shyan, Wong Peng, Sim, Benedict, Thahira, Jamal Mohamed, Tuang, Koh Mia, Yusoff, Nik, Choi, Jun Yong, Chan, Yu‐Jiun, Huang, Chih‐Sheng, Wing‐Wai, Wong, Avihingsanon, Anchalee, Chokephaibulkit, Kulkanya, Hansudewechakul, Rawiwan, Khumcha, Benjhawan, Khusuwan, Suwimon, Kiertiburanakul, Sasisopin, Lumbiganon, Pagakrong, Maleesatharn, Alan, Praparattanapan, Jutarat, Puthanakit, Thanyawee, Sricharoenchai, Sirintip, Sudjaritruk, Tavitiya, Watanaporn, Suporn, An, Vu Thien, Cuong, Duy, Hằng, Bùi Thu, Huy, Bùi Vũ, Quy, Du Tuan, and Van, Lam Nguyen
- Subjects
Health Services and Systems ,Biomedical and Clinical Sciences ,Clinical Sciences ,Health Sciences ,HIV/AIDS ,Infectious Diseases ,Sexually Transmitted Infections ,Health Disparities ,Health Services ,Women's Health ,Clinical Research ,Behavioral and Social Science ,Prevention ,Health and social care services research ,8.1 Organisation and delivery of services ,Infection ,Good Health and Well Being ,Adult ,Anti-HIV Agents ,CD4 Lymphocyte Count ,Delivery of Health Care ,Female ,Global Health ,HIV Infections ,HIV-1 ,Health Facilities ,Humans ,Male ,Surveys and Questionnaires ,Time Factors ,World Health Organization ,HIV ,"Treat all" ,antiretroviral treatment ,HIV care ,guideline implementation ,IeDEA Consortium ,“Treat all” ,Public Health and Health Services ,Other Medical and Health Sciences ,Clinical sciences ,Epidemiology ,Public health - Abstract
IntroductionSince 2015, the World Health Organization (WHO) has recommended that all people living with HIV (PLHIV) initiate antiretroviral treatment (ART), irrespective of CD4+ count or clinical stage. National adoption of universal treatment has accelerated since WHO's 2015 "Treat All" recommendation; however, little is known about the translation of this guidance into practice. This study aimed to assess the status of Treat All implementation across regions, countries, and levels of the health care delivery system.MethodsBetween June and December 2017, 201/221 (91%) adult HIV treatment sites that participate in the global IeDEA research consortium completed a survey on capacity and practices related to HIV care. Located in 41 countries across seven geographic regions, sites provided information on the status and timing of site-level introduction of Treat All, as well as site-level practices related to ART initiation.ResultsAlmost all sites (93%) reported that they had begun implementing Treat All, and there were no statistically significant differences in site-level Treat All introduction by health facility type, urban/rural location, sector (public/private) or country income level. The median time between national policy adoption and site-level introduction was one month. In countries where Treat All was not yet adopted in national guidelines, 69% of sites reported initiating all patients on ART, regardless of clinical criteria, and these sites had been implementing Treat All for a median period of seven months at the time of the survey. The majority of sites (77%) reported typically initiating patients on ART within 14 days of confirming diagnosis, with 60% to 62% of sites implementing Treat All in East, Southern and West Africa reporting same-day ART initiation for most patients.ConclusionsBy mid- to late-2017, the Treat All strategy was the standard of care at almost all IeDEA sites, including rural, primary-level health facilities in low-resource settings. While further assessments of site-level capacity to provide high-quality HIV care under Treat All and to support sustained viral suppression after ART initiation are needed, the widespread introduction of Treat All at the service delivery level is a critical step towards global targets for ending the HIV epidemic as a public health threat.
- Published
- 2019
5. Factors associated with reduced function and quality of life among adult people with HIV with depression and substance use in the Asia-Pacific region
- Author
-
Rajasuriar, Reena, Chong, Meng Li, Ross, Jeremy L., Jiamsakul, Awachana, Avihingsanon, Anchalee, Lee, Man Po, Ditangco, Rossana, Choi, Jun Yong, Gatechompol, Sivaporn, Chan, Iris, Melgar, Maria Isabel Echanis, Kim, Jung Ho, Sohn, Annette H., and Law, Matthew
- Published
- 2023
- Full Text
- View/download PDF
6. Risk factors for toxoplasmosis in people living with HIV in the Asia-Pacific region.
- Author
-
Lee, Ki Hyun, Jiamsakul, Awachana, Kiertiburanakul, Sasisopin, Borse, Rohidas, Khol, Vohith, Yunihastuti, Evy, Azwa, Iskandar, Somia, I. Ketut Agus, Chaiwarith, Romanee, Pham, Thach Ngoc, Khusuwan, Suwimon, Do, Cuong Duy, Kumarasamy, Nagalingeswaran, Gani, Yasmin, Ditangco, Rossana, Ng, Oon Tek, Pujari, Sanjay, Lee, Man Po, Avihingsanon, Anchalee, and Chen, Hsin-Pai
- Subjects
HEPATITIS B virus ,TOXOPLASMOSIS ,HIV-positive persons ,NON-nucleoside reverse transcriptase inhibitors ,HEPATITIS associated antigen ,NUCLEOSIDE reverse transcriptase inhibitors - Abstract
Introduction: Toxoplasma gondii can cause symptomatic toxoplasmosis in immunodeficient hosts, including in people living with human immunodeficiency virus (PLWH), mainly because of the reactivation of latent infection. We assessed the prevalence of toxoplasmosis and its associated risk factors in PLWH in the Asia-Pacific region using data from the TREAT Asia Human Immunodeficiency Virus (HIV) Observational Database (TAHOD) of the International Epidemiology Databases to Evaluate AIDS (IeDEA) Asia-Pacific. Methods: This study included both retrospective and prospective cases of toxoplasmosis reported between 1997 and 2020. A matched case-control method was employed, where PLWH diagnosed with toxoplasmosis (cases) were each matched to two PLWH without a toxoplasmosis diagnosis (controls) from the same site. Sites without toxoplasmosis were excluded. Risk factors for toxoplasmosis were analyzed using conditional logistic regression. Results: A total of 269/9576 (2.8%) PLWH were diagnosed with toxoplasmosis in 19 TAHOD sites. Of these, 227 (84%) were reported retrospectively and 42 (16%) were prospective diagnoses after cohort enrollment. At the time of toxoplasmosis diagnosis, the median age was 33 years (interquartile range 28–38), and 80% participants were male, 75% were not on antiretroviral therapy (ART). Excluding 63 out of 269 people without CD4 values, 192 (93.2%) had CD4 ≤200 cells/μL and 162 (78.6%) had CD4 ≤100 cells/μL. By employing 538 matched controls, we found that factors associated with toxoplasmosis included abstaining from ART (odds ratio [OR] 3.62, 95% CI 1.81–7.24), in comparison to receiving nucleoside reverse transcriptase inhibitors plus non-nucleoside reverse transcriptase inhibitors, HIV exposure through injection drug use (OR 2.27, 95% CI 1.15–4.47) as opposed to engaging in heterosexual intercourse and testing positive for hepatitis B virus surface antigen (OR 3.19, 95% CI 1.41–7.21). Toxoplasmosis was less likely with increasing CD4 counts (51–100 cells/μL: OR 0.41, 95% CI 0.18–0.96; 101–200 cells/μL: OR 0.14, 95% CI 0.06–0.34; >200 cells/μL: OR 0.02, 95% CI 0.01–0.06), when compared to CD4 ≤50 cells/μL. Moreover, the use of prophylactic cotrimoxazole was not associated with toxoplasmosis. Conclusions: Symptomatic toxoplasmosis is rare but still occurs in PLWH in the Asia-Pacific region, especially in the context of delayed diagnosis, causing advanced HIV disease. Immune reconstitution through early diagnosis and ART administration remains a priority in Asian PLWH. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. HIV treatment outcomes among people who acquired HIV via injecting drug use in the Asia-Pacific region: a longitudinal cohort study
- Author
-
Han, Win Min, Jiamsakul, Awachana, Salleh, Nur Afiqah Mohd, Choi, Jun Yong, Huy, Bui Vu, Yunihastuti, Evy, Do, Cuong Duy, Merati, Tuti P., Gani, Yasmin M., Kiertiburanakul, Sasisopin, Zhang, Fujie, Chan, Yu-Jiun, Lee, Man-Po, Chaiwarith, Romanee, Ng, Oon Tek, Khusuwan, Suwimon, Ditangco, Rossana, Kumarasamy, Nagalingeswaran, Sangle, Shashikala, Ross, Jeremy, and Avihingsanon, Anchalee
- Subjects
Antiviral agents -- Patient outcomes ,Intravenous drug abuse -- Complications and side effects ,Health behavior -- Evaluation ,HIV infection -- Development and progression -- Drug therapy ,Health - Abstract
INTRODUCTION: Data on HIV treatment outcomes in people who inject drugs (PWID) in the Asia-Pacific are sparse despite the high burden of drug use. We assessed immunological and virological responses, AIDS-defining events and mortality among PWID receiving antiretroviral therapy (ART). METHODS: We investigated HIV treatment outcomes among people who acquired HIV via injecting drug use in the TREAT Asia HIV Observational Database (TAHOD) between January 2003 and March 2019. Trends in CD4 count and viral suppression (VS, HIV viral load RESULTS: Of 622 PWID from 12 countries in the Asia-Pacific, 93% were male and the median age at ART initiation was 31 years (IQR, 28 to 34). The median pre-ART CD4 count was 71 cells/[micro]L. CD4 counts increased over time, with a mean difference of 401 (95% CI, 372 to 457) cells/[micro]L at year-10 (n = 78). Higher follow-up HIV viral load and pre-ART CD4 counts were associated with smaller increases in CD4 counts. Among 361 PWID with [greater than or equal to]1 viral load after six months on ART, proportions with VS were 82%, 88% and 93% at 2- 5- and 10-years following ART initiation. There were 52 new AIDS-defining events and 50 deaths during 3347 person-years of follow-up (PYS) (incidence 3.05/100 PYS, 95% CI, 2.51 to 3.70). Previous AIDS or TB diagnosis, lower current CD4 count and adherence CONCLUSIONS: Despite improved outcomes over time, our findings highlight the need for rapid ART initiation and adherence support among PWID within Asian settings. Keywords: people who inject drugs; treatment outcomes; CD4 recovery; viral suppression; tuberculosis; HIV/AIDS; Asia-Pacific, 1 | INTRODUCTION Globally, injecting drug use is a major public health concern leading to substantial health burden and transmission risk of blood-borne infections from injecting equipment sharing behaviours. In [...]
- Published
- 2021
- Full Text
- View/download PDF
8. Service delivery challenges in HIV care during the first year of the COVID‐19 pandemic: results from a site assessment survey across the global IeDEA consortium
- Author
-
Brazier, Ellen, Ajeh, Rogers, Maruri, Fernanda, Musick, Beverly, Freeman, Aimee, Wester, C. William, Lee, Man?Po, Shamu, Tinei, Ramírez, Brenda Crabtree, D' Almeida, Marcelline, Wools?Kaloustian, Kara, Kumarasamy, N., Althoff, Keri N., Twizere, Christella, Grinsztejn, Beatriz, Tanser, Frank, Messou, Eugène, Byakwaga, Helen, Duda, Stephany N., Nash, Denis, Chansilpa, Chidchon, Dougherty, Trevor, Karminia, Azar, Law, Matthew, Ross, Jeremy, Sohn, Annette, Aguirre, Ivette, Baker, David, Bloch, Mark, Cabot, Safaa, Carr, Andrew, Couldwell, Deborah, Edwards, Sian, Eu, Beng, Farlow, Heather, Finlayson, Robert, Gunathilake, Manoji, Hazlewood, Cherie, Hoy, Jennifer, Langton?Lockton, Julian, Le, Jacqueline, Leprince, Elizabeth, Minc, Ariane, Moore, Richard, O'Sullivan, Maree, Roth, Norm, Rowling, Dianne, Russell, Darren, Ryder, Nathan, Saunders, Craig, Silvers, Julie, Smith, David J., Sowden, David, Sweeney, Grant, Tan, Lynn, Teague, Ricard, Templeton, David, Thng, Caroline, Woolley, Ian, Khol, Vohith, Ly, Penh Sun, Li, Tsz Hei, Po, Lee Man, Kinikar, Aarti, Kumarasamy, Nagalingeswaran, Mundhe, Sanjay, Pujari, Sanjay, Sangle, Shashikala, Nimkar, Smita, Jassin, Madelein, Kurniati, Nia, Merati, Tuti Parwati, Muktiarti, Dina, Amalia, Rizqi, Sukmawati, Ni Made Dewi Dian, Wati, Ketut Dewi Kumara, Yunihastuti, Evy, Tanuma, Junko, Choi, Jun Yong, Azwa, Raja Iskandar Shah Raja, Cheng, Chan Kwai, Gani, Yasmin Mohamed, Mohamed, Thahira Jamal, Moy, Fong Siew, Nallusamy, Revathy, Nor, Mohamad Zulfahami Mohd, Rudi, Nuraini, Shyan, Wong Peng, Yusoff, Nik Khairulddin Nik, Ditangco, Rossana, Chan, Yu?Jiun, Wu, Pei?Chieh, Wu, Ping?Feng, Avihingsanon, Anchalee, Chaiwarith, Romanee, Chokephaibulkit, Kulkanya, Khusuwan, Suwimon, Kiertiburanakul, Sasisopin, Kosalaraksa, Pope, Lumbiganon, Pagakrong, Ounchanam, Pradtana, Puthanakit, Thanyawee, Rungmaitree, Supattra, Solai, Nuttarika, Sudjaritruk, Tavitiya, An, Vu Thien, Cuong, Do Duy, Do, Chau Viet, Huy, Bui Vu, Quy, Tuan, Van Nguyen, Kinh, Nguyen, Luan, Nguyen, Van Lam, Nguyen, Yen Thi, Nong, Vuong Minh, Truong, Huu Khanh, Tuyen, Ngo Thi Thu, Mcgowan, Catherine C., Duda, Stephany, Cahn, Florencia, Cahn, Pedro, Cesar, Carina, Fink, Valeria, Sued, Omar, Coelho, Lara, Machado, Daisy Maria, Pinto, Jorge, Wolff, Marcelo, Rouzier, Vanessa, Padgett, Denis, Gotuzzo, Eduardo, Biziragusenyuka, Jérémie, Gateretse, Patrick, Nimbona, Pelagie, Niyonkuru, Olive, Twizere, Christelle, Anicetus, Surreng, Djenabou, Amadou, Enow, Priscilla, Mbu, Eyongetah, Manga, Martin, Ndobe, Mercy, Nasah, Judith, Ekossono, Elle Nathalie Syntyche, Bouseko, Mireille Teno, Kitetele, Faustin, Lelo, Patricia, Diafouka, Merlin Isidore Justin, Mafoua, Adolphe, Nsonde, Dominique Mahambou, Bihira, Uitonze Aime Maurice, Dusabe, Marie Chantal, Feza, Rosine, Habanabashaka, Jean Claude, Habumuremyi, Viateur, Igizeneza, Ernestine, Kamigisha, Anne Marie, Kubwimana, Gallican, Maniriho, Gilbert, Mbaraga, Gilbert, Muhoza, Benjamin, Mukakarangwa, Jeanne, Mukamana, Joyce, Mukanyirigira, Patricie, Mukeshimana, Yvone Claude, Munyaneza, Athanase, Murenzi, Gad, Musaninyange, Jacqueline, Nyiraneza, Jules Ndumuhire, Ntarambirwa, Fidele, Nyiraneza, Marie Louise, Tuyishime, Josette, Tuyishimire, Yvonne, Ubandutira, Alexis, Umugiraneza, Florance, Umugwaneza, Rosine, Uwamahoro, Olive, Uwamahoro, Pauline, Uwambaje, Marie Victoire, Uwimpuhwe, Clarisse, Uwiragiye, Siphora, Kuhn, Yee Yee, Adera, Felix, Adhiambo, Beatricec, Aggrey, Khaemba, Akadikor, Daniel, Ambulla, Felix, Apiyo, Dorah, Ariya, Patrick, Atemba, Naftal, Ayodi, Fridah, Benard, Chirchir, Bett, Maureen, Birgen, Serafine, Bwalei, Rael, Chebon, Nancy, Chebor, Valentine Jirry, Chebuiywo, Philip, Chemutai, Jacline, Chepkorir, Emily, Chepseba, Carolyne, Chirchir, John, Diero, Lameck, Dukwa, Benard, Elphas, Alice, Etyang, Tom, Idiama, Agnes, Jebichuko, Ann, Jepchumba, Delvine, Juma, Churchill, Juma, Maureen, Juma, Sheila, Kadima, Julie, Karani, Rose, Keitany, Christopher, Keter, Pricilla, Kiavoga, Lucy, Kibet, Harrison, Kimutai, Ruth, Kiplagat, Mutai, Kiprono, Wilfred, Kipruto, Nicholas Kogei, Kirimi, Asenath, Koech, Zeddy, Kosgei, Carolyne, Kutto, Karen, Kweyu, Mildred, Liech, Ephraim Kenneth, Limo, Milka, Maina, Rose, Marumbu, Priscah, Masese, Agnes, Mochotto, Patricia, Molly, Omudeck, Momanyi, Tom, Murutu, John W., Mwanda, Praxidis, Ndakalu, Lillian, Nderitu, Rose N., Obatsa, Sarah, Obiga, Fredrick, Oboya, Moses, Odhiambo, Joseph, Olaya, George, Omanyala, Oscar, Oray, Christine, Otieno, Molly, Otwane, Modesta Toto, Ouma, Paul, Owuor, Charles, Pepela, Doris Tutu, Pessah, Collins, Rotich, Evans, Rotich, Edwin K., Rutto, Titus C., Shikuku, Monica, Sibweche, Rose Naliaka, Simiyu, Robert Wanyonyi, Siria, Hellen, Some, Michael, Songok, Winnie Cherotich, Tanui, Immaculate, Wafula, Grace, Wambura, Rebecca, Wanjala, Ellah, Wanyama, Carolyne, Wanyonyi, Hellen, Woyakapel, Emmanuel, Zelbabel, Wandera, Gwimo, Dikengela, Kinyota, Ester, Lwali, Jerome, Lyamuya, Rita, Machemba, Richard, Mathias, Julia, Mkombachepa, Lilian, Mokiwa, Athuman, Mushi, Ombeni, Ndunguru, Charles, Ngonyani, Kapella, Nyaga, Charles, Ruta, Happiness, Urassa, Mark, Akanyihayo, James, Arinaitwe, Arnold, Batuuka, Jesca, Birungi, Walusimbi, Bugembe, John Nyanzi, Ddungu, Ahmed, Francis, Kato, Imran, Bangira, Kafuuma, George William, Kalulue, John Bosco, Kanaabi, Grace, Kanyesigye, Michale, Karuhanga, Godfery, Kasozi, Charles, Kasule, Godfrey, Katusime, Assumpta, Kibalama, Donozio, Kimera, Simon Peter, Kulusumu, Namatovu, Lule, Yusuf, Lwanga, Isaac, Mluindwa, Margaret, Moses, Jemba, Mubarak, Sseremba, Muggaga, Daniel, Mukalazi, Evelyn, Muleebwa, Joseph, Mulema, Derick, Musisi, Ivan, Muwawu, John, Muyindike, Winnie, Mwaka, Dick, Naava, Milly, Nabiyki, Immaculate, Nabusulwa, Agnes, Nakabugo, Dorah, Nakamya, Esther, Nakanwagi, Daisy, Nakato, Oliver, Nakayi, Lydian, Nakigozi, Patience, Nakku, Juliet, Nakuya, Juliet, Nakyomu, Justine, Namayanja, Joan, Namirembe, Sarah, Namugumya, Juliet, Namukasa, Ezereth, Namulindwa, Viola, Nankya, Irene, Nannyondo, Grace Mugagga, Nansamba, Harriet, Nansera, Denis, Nanyanzi, Brenda, Nanyonjo, Esther Celina, Nayiga, Irene, Opira, Isaac, Owarwo, Noela C., Resty, Sserunkuma, Semuwemba, Haruna, Senoga, Julius, Sseguya, Gerald, Ssekyewa, John Paul, Ssemakadde, Matthew, Tebajjwa, Jonah, Tugumisirize, Doreen, Tushemerirwe, Robinah, Waliyi, Kawuki, Althoff, Keri, Bishop, Jennifer, Gill, M J., Loutfy, Mona, Smith, Graham, Bamford, Laura, Black, Anthony, Brice, Asia, Brown, Sheldon, Colasanti, Jonathan, Duarte, Piper, Firnhaber, Cynthia, Goetz, Matthew, Grasso, Chris, Gripshover, Barbara, Horberg, Michael, Kelly, Rita, Levine, Ken, Luu, Mitchell, Marconi, Vincent, Maroney, Karen, Mayer, Kenneth, Mayor, Angel, Mcgowan, Catherine, Multani, Ami, Napravnik, Sonia, Nijhawan, Ank, Novak, Richard, Palella, Frank, Rodriguez, Maria C., Scott, Mia, Tedaldi, Ellen, Willig, James, Cornell, Morna, Davies, Mary?Ann, Egger, Matthias, Haas, Andreas, Bereng, Monkoe, Kalake, Maleshoane, Lenela, Keketso, Seretse, Relebohile, Chintenga, Matthews, Chiwoko, Jane, Gumulira, Joe, Huwa, Jacqueline, Maluwa, Rafique, Matanje, Beatrice, Mbewe, Ronald, Mfungwe, Sunshine, Mphande, Zakaliah, Tweya, Hannock, Rafael, Idiovino, Apolles, Patti, Beneke, Eunice, Dlamini, Siphephelo, Edson, Claire, Eley, Brian, Euvrard, Jonathan, Fatti, Geoffrey, Goeieman, Bridgette, Grimwood, Ashraf, Huang, David, Hugo, Susan, Ismail, Zahiera, Jennings, Lauren, Mathenjwa, Thulile, Monteith, Lizette, Mshweshwe, Zamuxolo, Ntuli, Mfundi, Ndlovu, En, Ndlozi, Hloniphile, Noyakaza, Sylvia, Prozesky, Hans, Rabie, Helena, Sipambo, Nosisa, Technau, Karl?Günter, Tembe, Thokozani, Xaba, Nontando, Njobvu, Thandiwe, Munthaly, Mary, Mwetwa, Elly, Kabeba, Gillian, Mwendafilumba, Derrick, Maanguka, Ethel, Manyika, Nelly, Mwansa, Chalwe, Banda, Future, Mwenda, Dickson, Bwalya, Abel, Shapi, Leah, Syame, Kasapo, Sashi, Rita, Mulenga, Chisha, Nanyangwe, Ruth, Chimbetete, Cleophas, Chinofunga, A., Mhike, J., Mubvigwi, E., Nyika, F., Quarter, Kumbirai Pise, Arikawa, Shino Chassagne, Becquet, Renaud, Bernard, Charlotte, Dabis, François, Desmonde, Sophie, Dahourou, Désiré, Ekouevi, Didier Koumavi, Jaquet, Antoine, Jesson, Julie, Leroy, Valeriane, Malateste, Karen, Rabourdin, Elodie, Tiendrebeogo, Thierry, Assogba, Michée, Zannou, Djimon Marcel, Hounhoui, Ghislaine, Bere, Denise, Poda, Armel, Pooda, Gbolo, Traore, Richard, Abauble, Yao, Abby, Ouattara, Acquah, Patrick, Andoble, Valérie, Aude, Yobo N'Dzama, Azani, Jean?Claude, Berete, Oka, Beugre, Jacques Daple, Bohoussou, Caroline Yao, Brou, Simon Boni Emmanuel, Chenal, Henri, Cissé, Abdoulaye, Coulibaly, Nambate, Dainguy, Marie Evelyne, Daligou, Marcelle, D' Aquin, Toni Thomas, Dasse, Claude Desire, Folquet, Madeleine Amorissani, Gnepa, Guy, Gobe, Olivier, Guira, Salif, Hawerlander, Denise, Horo, Apollinaire, Kanga, Guillaume, Messou, Zobo Konan Eugène, Minga, Kla Albert, Moh, Raoul, N'Gbeche, Mariesylvie, Ogbo, Patricia, Oulai, Mathieu, Stéphanie, Se, Eboua, Tanoh, Valère, Itchy Max, Afrane, Adwoa Kumiwa Asare, Akrofi, Esther, Andoh, John Christian, Renner, Lorna, Bagayoko, Awa, Bagayoko, Kadidiatou, Bah, Abdou Salam, Berthe, Alima, Coulibaly, Boureïma, Coulibaly, Fatimata, Coulibaly, Yacouba Aba, Diakité, Aïssata, Bocoum, Fatoumata, Boré, Fatoumata, Dicko, Fatoumata, Koné, Odile, Sylla, Mariam, Tangara, Assitan, Traoré, Mamadou, Seydi, Moussa, Amegatse, Edmond, Djossou, Julienne, Takassi, Elom, and Palanga, Sénam
- Subjects
HIV (Viruses) -- Care and treatment -- Patient outcomes ,Public health administration -- Evaluation ,Health - Abstract
: Introduction: Interruptions in treatment pose risks for people with HIV (PWH) and threaten progress in ending the HIV epidemic; however, the COVID‐19 pandemic's impact on HIV service delivery across diverse settings is not broadly documented. Methods: From September 2020 to March 2021, the International epidemiology Databases to Evaluate AIDS (IeDEA) research consortium surveyed 238 HIV care sites across seven geographic regions to document constraints in HIV service delivery during the first year of the pandemic and strategies for ensuring care continuity for PWH. Descriptive statistics were stratified by national HIV prevalence ( Results: Questions about pandemic‐related consequences for HIV care were completed by 225 (95%) sites in 42 countries with low (n = 82), medium (n = 86) and high (n = 57) HIV prevalence, including low‐ (n = 57), lower‐middle (n = 79), upper‐middle (n = 39) and high‐ (n = 50) income countries. Most sites reported being subject to pandemic‐related restrictions on travel, service provision or other operations (75%), and experiencing negative impacts (76%) on clinic operations, including decreased hours/days, reduced provider availability, clinic reconfiguration for COVID‐19 services, record‐keeping interruptions and suspension of partner support. Almost all sites in low‐prevalence and high‐income countries reported increased use of telemedicine (85% and 100%, respectively), compared with less than half of sites in high‐prevalence and lower‐income settings. Few sites in high‐prevalence settings (2%) reported suspending antiretroviral therapy (ART) clinic services, and many reported adopting mitigation strategies to support adherence, including multi‐month dispensing of ART (95%) and designating community ART pick‐up points (44%). While few sites (5%) reported stockouts of first‐line ART regimens, 10–11% reported stockouts of second‐ and third‐line regimens, respectively, primarily in high‐prevalence and lower‐income settings. Interruptions in HIV viral load (VL) testing included suspension of testing (22%), longer turnaround times (41%) and supply/reagent stockouts (22%), but did not differ across settings. Conclusions: While many sites in high HIV prevalence settings and lower‐income countries reported introducing or expanding measures to support treatment adherence and continuity of care, the COVID‐19 pandemic resulted in disruptions to VL testing and ART supply chains that may negatively affect the quality of HIV care in these settings., INTRODUCTION The COVID‐19 pandemic has had major direct and indirect impacts on population health globally, through disruptions in the accessibility and quality of basic health services [1], in supply chains [...]
- Published
- 2022
- Full Text
- View/download PDF
9. Mpox vaccination for men who have sex with men and their differential risk of exposure and infection
- Author
-
Wong, Ngai Sze, primary, Wong, Bonnie Chun-Kwan, additional, Lee, Man-Po, additional, Tsang, Owen Tak-Yin, additional, Cheung, Danny King Fai, additional, Sit, Alfred Yao-Wai, additional, Wong, Samuel Yeung-Shan, additional, and Lee, Shui-Shan, additional
- Published
- 2023
- Full Text
- View/download PDF
10. Validation of the D: A: D Chronic Kidney Disease Risk Score Model among people living with HIV in the Asia-Pacific
- Author
-
Han, Win Min, Bijker, Rimke, Chandrasekaran, Ezhilarasi, Pujari, Sanjay, Ng, Oon Tek, Ly, Penh Sun, Lee, Man-Po, Van Nguyen, Kinh, Chan, Yu-Jiun, Do, Cuong Duy, Choi, Jun Yong, Chaiwarith, Romanee, Merati, Tuti Parwati, Kiertiburanakul, Sasisopin, Azwa, Iskandar, Khusuwan, Suwimon, Zhang, Fujie, Gani, Yasmin Mohamed, Tanuma, Junko, Sangle, Shashikala, Ditangco, Rossana, Yunihastuti, Evy, Ross, Jeremy, and Avihingsanon, Anchalee
- Published
- 2020
- Full Text
- View/download PDF
11. Cotrimoxazole prophylaxis decreases tuberculosis risk among Asian patients with HIV
- Author
-
Ku, Stephane Wen-Wei, Jiamsakul, Awachana, Joshi, Kedar, Pasayan, Mark Kristoffer Ungos, Widhani, Alvina, Chaiwarith, Romanee, Kiertiburanakul, Sasisopin, Avihingsanon, Anchalee, Ly, Penh Sun, Kumarasamy, Nagalingeswaran, Do, Cuong D., Merati, Tuti P., Van Nguyen, Kinh, Kamarulzaman, Adeeba, Zhang, Fujie, Lee, Man Po, Choi, Jun Yong, Tanuma, Junko, Khusuwan, Suwimon, Sim, Benedict Lim Heng, Ng, Oon Tek, Ratanasuwan, Winai, Ross, Jeremy, and Wong, Wing-Wai
- Subjects
HIV patients -- Drug therapy ,Prophylaxis -- Testing ,Tuberculosis -- Drug therapy -- Risk factors -- Prevention ,Trimethoprim-sulfamethoxazole (Drug combination) -- Testing ,Health - Abstract
Introduction: Cotrimoxazole (CTX) is recommended as prophylaxis against Pneumocystis jiroveci pneumonia, malaria and other serious bacterial infections in HIV-infected patients. Despite its in vitro activity against Mycobacterium tuberculosis, the effects of CTX preventive therapy on tuberculosis (TB) remain unclear. Methods: Adults living with HIV enrolled in a regional observational cohort in Asia who had initiated combination antiretroviral therapy (cART) were included in the analysis. Factors associated with new TB diagnoses after cohort entry and survival after cART initiation were analysed using Cox regression, stratified by site. Results: A total of 7355 patients from 12 countries enrolled into the cohort between 2003 and 2016 were included in the study. There were 368 reported cases of TB after cohort entry with an incidence rate of 0.99 per 100 person-years (/100 pys). Multivariate analyses adjusted for viral load (VL), CD4 count, body mass index (BMI) and cART duration showed that CTX reduced the hazard for new TB infection by 28% (HR 0.72, 95% CI l 0.56, 0.93). Mortality after cART initiation was 0.85/100 pys, with a median follow-up time of 4.63 years. Predictors of survival included age, female sex, hepatitis C co-infection, TB diagnosis, HIV VL, CD4 count and BMI. Conclusions: CTX was associated with a reduction in the hazard for new TB infection but did not impact survival in our Asian cohort. The potential preventive effect of CTX against TB during periods of severe immunosuppression should be further explored. Keywords: cotrimoxazole; sulphamethoxazole/trimethoprim; tuberculosis; HIV; AIDS; Asia; cohort studies; prophylaxis, 1 | INTRODUCTION Cotrimoxazole (CTX) has been recommended as prophylaxis against Pneumocystis jiroveci pneumonia (PJP), toxoplasmosis, malaria and other serious bacterial infections in adults with severe or advanced HIV clinical [...]
- Published
- 2019
- Full Text
- View/download PDF
12. The influence of age-associated comorbidities on responses to combination antiretroviral therapy in older people living with HIV
- Author
-
Ahn, Mi Young, Jiamsakul, Awachana, Khusuwan, Suwimon, Khol, Vohith, Pham, Thuy T., Chaiwarith, Romanee, Avihingsanon, Anchalee, Kumarasamy, Nagalingeswaran, Wong, Wing Wei, Kiertiburanakul, Sasisopin, Pujari, Sanjay, Nguyen, Kinh V., Lee, Man Po, Kamarulzaman, Adeeba, Zhang, Fujie, Ditangco, Rossana, Merati, Tuti P., Yunihastuti, Evy, Ng, Oon Tek, Sim, Benedict L.H., Tanuma, Junko, Ratanasuwan, Winai, Ross, Jeremy, and Choi, Jun Yong
- Subjects
HIV patients -- Health aspects -- Care and treatment ,Highly active antiretroviral therapy -- Usage ,HIV infections -- Care and treatment ,Comorbidity -- Risk factors ,Quality of life -- Analysis ,Health - Abstract
Introduction: Multiple comorbidities among HIV-positive individuals may increase the potential for polypharmacy causing drug-to-drug interactions and older individuals with comorbidities, particularly those with cognitive impairment, may have difficulty in adhering to complex medications. However, the effects of age-associated comorbidities on the treatment outcomes of combination antiretroviral therapy (cART) are not well known. In this study, we investigated the effects of age-associated comorbidities on therapeutic outcomes of cART in HIV-positive adults in Asian countries. Methods: Patients enrolled in the TREAT Asia HIV Observational Database cohort and on cART for more than six months were analysed. Comorbidities included hypertension, diabetes, dyslipidaemia and impaired renal function. Treatment outcomes of patients [greater than or equal to]50 years of age with comorbidities were compared with those Results: The incidence of virologic failure was 7.72/100 person-years. Virological failure was less likely in patients with better adherence and higher CD4 count at cART initiation. Those acquiring HIV through intravenous drug use were more likely to have virological failure compared to those infected through heterosexual contact. On univariate analysis, patients aged Conclusions: In our Asia regional cohort, age-associated comorbidities did not affect virologic outcomes of cART. Among those with comorbidities, patients Keywords: HIV; cART; age-associated comorbidity; immunological failure; virological failure; TAHOD (TREAT Asia HIV Observational Database), 1 | INTRODUCTION Combination antiretroviral therapy (cART) has dramatically improved the survival and quality of life for people living with HIV [1-3]. A growing proportion of patients are over the [...]
- Published
- 2019
- Full Text
- View/download PDF
13. A pseudo-random patient sampling method evaluated
- Author
-
De La Mata, Nicole L., Ahn, Mi-Young, Kumarasamy, Nagalingeswaran, Ly, Penh Sun, Ng, Oon Tek, Nguyen, Kinh Van, Merati, Tuti Parwati, Pham, Thuy Thanh, Lee, Man Po, Durier, Nicolas, and Law, Matthew G.
- Published
- 2017
- Full Text
- View/download PDF
14. Incidence of hepatocellular carcinoma and mortality in chronic viral hepatitis in an Asian population with and without HIV infection.
- Author
-
Lui, Grace Chung‐Yan, Hui, Vicki Wing‐Ki, Sze, Shun‐Fung, Wong, Bonnie Chun‐Kwan, Cheung, Catherine, Lee, Man‐Po, Yip, Terry Cheuk‐Fung, Tse, Yee‐Kit, Lai, Jimmy Che‐To, Chan, Henry Lik‐Yuen, Wong, Vincent Wai‐Sun, Hui, Yee‐Tak, and Wong, Grace Lai‐Hung
- Subjects
HIV infections ,VIRAL hepatitis ,CHRONIC active hepatitis ,HEPATOCELLULAR carcinoma ,ASIANS ,PROPORTIONAL hazards models ,HIV-positive persons - Abstract
Summary: Background: It is uncertain whether people with HIV infection have a higher incidence of hepatocellular carcinoma (HCC) than the general population. Aims: To compare the incidence of HCC between people infected with HBV and/or HCV with and without HIV Methods: We performed a retrospective population‐based cohort study, involving people with HBV and/or HCV infection from 2001 to 2018. The primary endpoint was incidence of HCC; secondary endpoint was all‐cause mortality. We performed Cox proportional hazard regression models to estimate the hazard ratios (HR) of HIV for the primary and secondary endpoints. Results: We identified 1374 people infected with HIV and 39,908 people without HIV with HBV and/or HCV infection. Among those with HIV, 654 (47.6%) had HBV, 649 (47.2%) HCV and 71 (5.2%) HBV‐HCV‐co‐infection; they were younger, and had a higher prevalence of HCV and a lower prevalence of cirrhosis. The incidence rate estimates of HCC were, respectively, 1.5 (95% CI: 0.8–2.5) and 7.6 (95% CI 7.3‐8.0) per 1000 person‐years for those with and without HIV infection. Using multivariate Cox proportional hazard regression models, among people with HBV, HIV was associated with lower risk of HCC (adjusted HR: 0.376, 95% CI: 0.201–0.704, p = 0.01) and death (adjusted HR: 0.692, 95% CI: 0.552–0.867, p = 0.007). Risks of HCC were similar for HCV and HBV‐HCV co‐infection for people with and without HIV. Conclusions: Among individuals with HBV infection, the Incidence of HCC was lower in those with HIV. For HCV infection, incidence of HCC was similar between those with and without HIV. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. Sex-based differences in antiretroviral therapy initiation, switching and treatment interruptions: global overview from the International Epidemiologic Databases to Evaluate AIDS (IeDEA)
- Author
-
Giles, Michelle L, Achhra, Amit C, Abraham, Alison G, Haas, Andreas D, Gill, Michael John, Lee, Man Po, Luque, Marco, McGowan, Catherine, Cornell, Morna, Braitstein, Paula, de Rekeneire, Nathalie, Becquet, Renaud, Wools-Kaloustian, Kara, and Law, Matthew
- Subjects
HIV infections -- Drug therapy -- Research ,Antiretroviral agents -- Dosage and administration ,Sex differences (Biology) -- Research ,Health - Abstract
Introduction: In 2015, the World Health Organization recommended that all HIV-infected individuals consider ART initiation as soon as possible after diagnosis. Sex differences in choice of initial ART regimen, indications for switching, time to switching and choice of second-line regimens have not been well described. The aims of this study were to describe first-line ART and CD4 count at ART initiation by sex, calendar year and region, and to analyse time to change or interruption in first-line ART, according to sex in each region. Methods: Participating cohorts included: Southern, East and West Africa (IeDEA-Africa), North America (NA-ACCORD), Caribbean, Central/South America (CCASAnet) and Asia-Pacific including Australia (IeDEA Asia-Pacific). The primary outcomes analysed for each region and according to sex were choice of initial ART, time to switching and time to discontinuation of the first-line regimen. Results and Discussion: The combined cohort data set comprised of 715,252 participants across seven regions from low- to high-income settings. The median CD4 count at treatment initiation was lower in men compared with women in nearly all regions and time periods. Women from North America and Southern Africa were more likely to switch ART compared to men (p < 0.001) with approximately 90% of women reporting a major change after 10 years in North America. Overall, after 8 years on ART, >50% of HIV- positive men and women from Southern Africa, East Africa, South and Central America remained on their original regimen. Men were more likely to have a treatment interruption compared with women in low- and middle-income countries from the Asia/Pacific region (p < 0.001) as were men from Southern Africa (p < 0.001). Greater than 75% of men and women did not report a treatment interruption after 10 years on ART from all regions except North America and Southern Africa. Conclusions: There are regional variations in the ART regimen commenced at baseline and rates of major change and treatment interruption according to sex. Some of this is likely to reflect changes in local and international antiretroviral guideline recommendations but other sex-specific factors such as pregnancy may contribute to these differences. Keywords: cohort studies; gender; treatment; women; sex; HIV, 1 | INTRODUCTION Over the past decade, HIV treatment guidelines have changed, with the CD[4.sup.+] count threshold for initiating antiretroviral therapy (ART) gradually increasing from less than 350 cells/[micro]L in [...]
- Published
- 2018
- Full Text
- View/download PDF
16. The treatment outcomes of antiretroviral substitutions in routine clinical settings in Asia; data from the TREAT Asia HIV Observational Database (TAHOD)
- Author
-
Jung, In Young, Boettiger, David, Wong, Wing Wai, Lee, Man Po, Kiertiburanakul, Sasisopin, Chaiwarith, Romanee, Avihingsanon, Anchalee, Tanuma, Junko, Kumarasamy, Nagalingeswaran, Kamarulzaman, Adeeba, Zhang, Fujie, Kantipong, Pacharee, Ng, Oon Tek, Sim, Benedict Lim Heng, Law, Matthew, Ross, Jeremy, and Choi, Jun Yong
- Subjects
Health - Abstract
Introduction: Although substitutions of antiretroviral regimen are generally safe, most data on substitutions are based on results from clinical trials. The objective of this study was to evaluate the treatment outcomes of substituting antiretrovira regimen in virologically suppressed HIV-infected patients in non-clinical trial settings in Asian countries.Methods: The study population consisted of HIV-infected patients enrolled in the TREAT Asia HIV Observational Database (TAHOD). Individuals were included in this analysis if they started combination antiretroviral treatment (cART) after 2002, were being treated at a centre that documented a median rate of viral load monitoring >0.8 tests/patient/year among TAHOD enrolees, and experienced a minor or major treatment substitution while on virally suppressive cART. The primary endpoint to evaluate outcomes was clinical or virological failure (VF), followed by an ART class change. Clinical failure was defined as death or an AIDS diagnosis. VF was defined as confirmed viral load measurements >400 copies/mL followed by an ART class change within six months. Minor regimen substitutions were defined as within-class changes and major regimen substitutions were defined as changes to a drug class. The patterns of substitutions and rate of clinical or VF after substitutions were analyzed.Results: Of 3994 adults who started ART after 2002, 3119 (78.1%) had at least one period of virological suppression. Among these, 1170 (37.5%) underwent a minor regimen substitution, and 296 (9.5%) underwent a major regimen substitution during suppression. The rates of clinical or VF were 1.48/100 person years (95% CI 1.14 to 1.91) in the minor substitution group, 2.85/100 person years (95% CI 1.88 to 4.33) in the major substitution group and 2.53/100 person years (95% CI 2.20 to 2.92) among patients that did not undergo a treatment substitution.Conclusions: The rate of clinical or VF was low in both major and minor substitution groups, showing that regimen substitution is generally effective in non-clinical trial settings in Asian countries.Keywords: ART; substitution; Asian countries; clinical failure; virological failure; effectiveness, 1 | INTRODUCTIONCombination antiretroviral treatments (cART) have been widely available in Asia since 2003 [1]. However, most Asian HIV clinics have limited resources and are able to prescribe regimens based [...]
- Published
- 2017
- Full Text
- View/download PDF
17. Factors associated with reduced function and quality of life among adult people with HIV with depression and substance use in the Asia-Pacific region
- Author
-
Rajasuriar, Reena, primary, Chong, Meng Li, additional, Ross, Jeremy L., additional, Jiamsakul, Awachana, additional, Avihingsanon, Anchalee, additional, Lee, Man Po, additional, Ditangco, Rossana, additional, Choi, Jun Yong, additional, Gatechompol, Sivaporn, additional, Chan, Iris, additional, Melgar, Maria Isabel Echanis, additional, Kim, Jung Ho, additional, Sohn, Annette H., additional, and Law, Matthew, additional
- Published
- 2022
- Full Text
- View/download PDF
18. The differential impacts of early detection and accelerated antiretroviral therapy on the epidemiologic trend of sexually acquired HIV infection in Hong Kong
- Author
-
Poon, Paul Kwok-ming, primary, Wong, Ngai-sze, additional, Leung, Wai-shing, additional, Wong, Bonnie Chun-kwan, additional, Kwong, Tsz-shan, additional, Kwan, Tsz-ho, additional, Lui, Grace Chung-yan, additional, Tsang, Owen Tak-yin, additional, Lee, Man-po, additional, Wong, Ka-hing, additional, and Lee, Shui-shan, additional
- Published
- 2022
- Full Text
- View/download PDF
19. Trends in hepatitis C virus coinfection and its cascade of care among adults living with HIV in Asia between 2010 and 2020.
- Author
-
Ross, Jeremy, Rupasinghe, Dhanushi, Avihingsanon, Anchalee, Lee, Man Po, Pujari, Sanjay, Sharp, Gerald, Kumarasamy, Nagalingeswaran, Khusuwan, Suwimon, Khol, Vohith, Agus Somia, I. Ketut, Pham, Thach Ngoc, Kiertiburanakul, Sasisopin, Choi, Jun Yong, Duy Do, Cuong, Sohn, Annette H., and Jiamsakul, Awachana
- Subjects
HIV ,HEPATITIS C virus ,CHRONIC hepatitis C ,MIXED infections ,HIV infections ,HIGH-income countries ,ADULTS - Abstract
Background: Chronic hepatitis C virus (HCV) infection contributes to substantial morbidity and mortality among adults living with HIV. Cascades of HCV care support monitoring of program performance, but data from Asia are limited. We assessed regional HCV coinfection and cascade outcomes among adults living with HIV in care from 2010–2020. Methods: Patients ≥18 years old with confirmed HIV infection on antiretroviral therapy (ART) at 11 clinical sites in Cambodia, China, India, Indonesia, South Korea, Thailand and Vietnam were included. HCV- and HIV-related treatment and laboratory data were collected from those with a positive HCV antibody (anti-HCV) test after January 2010. An HCV cascade was evaluated, including proportions positive for anti-HCV, tested for HCV RNA or HCV core antigen (HCVcAg), initiated on HCV treatment, and achieved sustained virologic response (SVR). Factors associated with screening uptake, treatment initiation, and treatment response were analyzed using Fine and Gray's competing risk regression model. Results: Of 24,421 patients, 9169 (38%) had an anti-HCV test, and 971 (11%) had a positive result. The proportion with positive anti-HCV was 12.1% in 2010–2014, 3.9% in 2015–2017, and 3.8% in 2018–2020. From 2010 to 2014, 34% with positive anti-HCV had subsequent HCV RNA or HCVcAg testing, 66% initiated HCV treatment, and 83% achieved SVR. From 2015 to 2017, 69% with positive anti-HCV had subsequent HCV RNA or HCVcAg testing, 59% initiated HCV treatment, and 88% achieved SVR. From 2018 to 2020, 80% had subsequent HCV RNA or HCVcAg testing, 61% initiated HCV treatment, and 96% achieved SVR. Having chronic HCV in later calendar years and in high-income countries were associated with increased screening, treatment initiation or achieving SVR. Older age, injecting drug use HIV exposure, lower CD4 and higher HIV RNA were associated with reduced HCV screening or treatment initiation. Conclusions: Our analysis identified persistent gaps in the HCV cascade of care, highlighting the need for focused efforts to strengthen chronic HCV screening, treatment initiation, and monitoring among adult PLHIV in the Asia region. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
20. Pre-exposure prophylaxis (PrEP) for MSM in low HIV incidence places: should high risk individuals be targeted?
- Author
-
Wong, Ngai Sze, Kwan, Tsz Ho, Tsang, Owen T. Y., Lee, Man Po, Yam, Wing Cheong, Lam, Wilson, Leung, Wai Shing, Chan, Jacky M. C., Ho, Kai Man, and Lee, Shui Shan
- Published
- 2018
- Full Text
- View/download PDF
21. CD4/CD8 Ratio Recovery Among People Living With HIV Starting With First-Line Integrase Strand Transfer Inhibitors: A Prospective Regional Cohort Analysis.
- Author
-
Han, Win Min, Avihingsanon, Anchalee, Rajasuriar, Reena, Tanuma, Junko, Mundhe, Sanjay, Lee, Man-Po, Choi, Jun Yong, Pujari, Sanjay, Chan, Yu-Jiun, Somia, Agus, Zhang, Fujie, Kumarasamy, Nagalingeswaran, Tek NG, Oon, Gani, Yasmin, Chaiwarith, Romanee, Pham, Thach Ngoc, Do, Cuong Duy, Ditangco, Rossana, Kiertiburanakul, Sasisopin, and Khol, Vohith
- Published
- 2023
- Full Text
- View/download PDF
22. Development of an HIV Clinical Cohort Database for Enhancing Epidemiologic Surveillance in Hong Kong
- Author
-
Lee, Shui Shan, Lee, Krystal Chi Kei, Lee, Man Po, Tse, Ian Chi Tat, Mak, Wai Lai, Li, Patrick Chung Ki, Wong, Ka Hing, and Sung, Joseph Jao Yiu
- Published
- 2011
23. Short-Term Clinical Disease Progression in HIV-Infected Patients Receiving Combination Antiretroviral Therapy: Results from the TREAT Asia HIV Observational Database
- Author
-
Srasuebkul, Preeyaporn, Lim, Poh Lian, Lee, Man Po, Kumarasamy, Nagalingeswaran, Zhou, Jialun, Sirisanthana, Thira, Li, Patrick C. K., Kamarulzaman, Adeeba, Oka, Shinichi, Phanuphak, Praphan, Vonthanak, Saphonn, Merati, Tuti P., Chen, Yi-Ming A., Sungkanuparph, Somnuek, Tau, Goa, Zhang, Fujie, Lee, Christopher K. C., Ditangco, Rossana, Pujari, Sanjay, Choi, Jun Y., Smith, Jeffery, and Law, Matthew G.
- Published
- 2009
- Full Text
- View/download PDF
24. Effects of unplanned treatment interruptions on HIV treatment failure – results from TAHOD
- Author
-
Jiamsakul, Awachana, Kerr, Stephen J., Ng, Oon Tek, Lee, Man Po, Chaiwarith, Romanee, Yunihastuti, Evy, Van Nguyen, Kinh, Pham, Thuy Thanh, Kiertiburanakul, Sasisopin, Ditangco, Rossana, Saphonn, Vonthanak, Sim, Benedict L. H., Merati, Tuti Parwati, Wong, Wingwai, Kantipong, Pacharee, Zhang, Fujie, Choi, Jun Yong, Pujari, Sanjay, Kamarulzaman, Adeeba, Oka, Shinichi, Mustafa, Mahiran, Ratanasuwan, Winai, Petersen, Boondarika, Law, Matthew, Kumarasamy, Nagalingeswaran, Mean, CV, Khol, V, Zhao, HX, Han, N, Li, PCK, Lam, W, Chan, YT, Saghayam, S, Ezhilarasi, C, Joshi, K, Gaikwad, S, Chitalikar, A, Wirawan, DN, Yuliana, F, Imran, D, Widhani, A, Tanuma, J, Nishijima, T, Na, S, Kim, JM, Gani, YM, David, R, Omar, SF Syed, Ponnampalavanar, S, Azwa, I, Nordin, N, Uy, E, Bantique, R, Ku, WW, Wu, PC, Lim, PL, Lee, LS, Ohnmar, PS, Ruxrungtham, K, Avihingsanon, A, Chusut, P, Sungkanuparph, S, Chumla, L, Sanmeema, N, Sirisanthana, T, Kotarathititum, W, Praparattanapan, J, Kambua, P, Sriondee, R, Bui, VH, Nguyen, THD, Cuong, DD, Ha, HL, Sohn, AH, Durier, N, Petersen, B, Jiamsakul, A, and Boettiger, DC
- Published
- 2016
- Full Text
- View/download PDF
25. Factors associated with high alanine aminotransferase (ALT) and cirrhosis in people living with HIV on combination antiretroviral treatment (cART) in the Asia‐Pacific.
- Author
-
Rupasinghe, Dhanushi, Choi, Jun Yong, Yunihastuti, Evy, Kiertiburanakul, Sasisopin, Ross, Jeremy, Ly, Penh Sun, Chaiwarith, Romanee, Do, Cuong Duy, Chan, Yu‐Jiun, Kumarasamy, Nagalingeswaran, Avihingsanon, Anchalee, Kamarulzaman, Adeeba, Khusuwan, Suwimon, Zhang, Fujie, Lee, Man Po, Van Nguyen, Kinh, Merati, Tuti Parwati, Sangle, Sashikala, Oon Tek, Ng, and Tanuma, Junko
- Subjects
HIV-positive persons ,ALANINE aminotransferase ,ANTIRETROVIRAL agents ,CIRRHOSIS of the liver ,HEPATITIS C virus - Abstract
Liver disease is a growing burden among people living with HIV (PLHIV) in resource‐limited settings. As an indicator of liver disease, risk factors of high alanine aminotransferase (ALT) and cirrhosis were assessed among PLHIV in the TREAT Asia HIV Observational Database (TAHOD). Patients on combination antiretroviral therapy (cART) with a pre‐cART ALT measurement and at least one follow‐up ALT measurement were included. Factors associated with high ALT (ALT levels > 5 times its upper limit of normal) were analyzed using repeated measure logistic regression over a 10‐year follow‐up period. Liver cirrhosis was defined as having an AST to Platelet Ratio Index score > 1.5, fibrosis‐4 score > 3.25, or a clinical diagnosis of cirrhosis. Cox regression analysis stratified by site was used to analyze factors associated with cirrhosis among those in follow‐up after 2015. Of 5182 patients, 101 patients (1.9%) had high ALT levels with hepatitis C virus (HCV) antibody positive (odds ratio [OR]: 4.98, 95% confidence interval [CI]: 2.82–8.77, p < 0.001) and ever high alcohol consumption (OR: 2.33, 95% CI: 1.00–5.46, p = 0.050) as likely factors. Among 6318 PLHIV in the liver cirrhosis analysis, 151 (2%) developed cirrhosis (incidence rate = 0.82 per 100 person‐years). Those HCV‐antibody positive (hazard ratio [HR]: 5.54, 95% CI: 3.75–8.18, p < 0.001) and had high alcohol consumption (HR: 2.06, 95% CI: 1.23–3.45, p = 0.006) were associated with liver cirrhosis. HCV‐antibody positive and high alcohol consumption are factors associated with high ALT. With raised ALT levels as a known factor associated with liver cirrhosis, greater efforts are required in managing ALT levels and reducing the risk of developing liver cirrhosis among those positive for HCV‐antibody and those who consume alcohol. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
26. Viral hepatitis and the cascade of care among people living with HIV in the Asia‐Pacific.
- Author
-
Rupasinghe, Dhanushi, Choi, Jun Yong, Kumarasamy, Nagalingeswaran, Pujari, Sanjay, Sun, Ly Penh, Merati, Tuti Parwati, Lee, Man Po, Kinh, Nguyen Van, Kiertiburanakul, Sasisopin, Do, Cuong Duy, Avihingsanon, Anchalee, Ross, Jeremy, and Jiamsakul, Awachana
- Subjects
HEPATITIS B ,VIRAL hepatitis ,VIRAL load ,HEPATITIS C ,HEALTH outcome assessment ,HIGHLY active antiretroviral therapy ,CONTINUUM of care ,MIXED infections ,DESCRIPTIVE statistics ,DATA analysis software ,PSYCHOLOGY of HIV-positive persons ,LONGITUDINAL method ,ANTIGENS - Abstract
Background: Although the prevalence and mortality of hepatitis is high in the Asia‐Pacific region, few studies are available on the diagnosis, treatment, and cure rates for viral hepatitis among people living with HIV in this area. This study aims to report the cascade of care (CoC) for hepatitis B (HBV) and C (HCV) among people living with HIV receiving combined antiretroviral therapy (ART). Methods: Patients enrolled in the TREAT Asia HIV Observational Database Low Intensity Transfer (TAHOD‐LITE) cohort, on ART, and with follow‐up data from 2010 to 2019 were included. Patients were determined as positive for HCV or HBV co‐infection if they ever tested positive for HCV antibody (anti‐HCV) or HBV surface antigen (HBsAg), respectively. Results: In total, 39% (8612/22 340) of the adult HIV cohort had undergone HBsAg testing, with 8% (672/8612) testing positive. HBV CoC demonstrated that 71% (474/672) of those with HBsAg positive results initiated treatment, 67% (318/474) of those on treatment had HBV DNA testing to evaluate treatment progression, and 18% (58/318) of those tested reached viral suppression. Of the cohort, 37% (8231/22 340) had anti‐HCV testing, of whom 10% (779/8231) tested positive. The HCV CoC showed that 68% (526/779) of those with positive anti‐HCV tests had HCV RNA tests, of whom 51% (267/526) had detectable HCV RNA. Among those with detectable HCV RNA, 65% (174/267) initiated HCV treatment. Of the 40% (69/174) who initiated HCV treatment, 90% (62/69) reached sustained virological response. Conclusion: Our findings identified less frequent testing in the healthcare system and limited access to treatment as gaps in the CoC for viral hepatitis. More routine HCV RNA and HBV DNA testing is required for patients with positive screening tests to identify those in need of treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
27. Transmitted drug resistance profile of men who have sex with men newly diagnosed with HIV in Hong Kong
- Author
-
Kwan, Tsz-Ho, primary, Wong, Ngai-Sze, additional, Lui, Grace Chung-Yan, additional, Wong, Bonnie Chun-Kwan, additional, Tsang, Owen Tak-Yin, additional, Leung, Wai-Shing, additional, Lee, Man-Po, additional, Chan, Denise Pui-Chung, additional, and Lee, Shui-Shan, additional
- Published
- 2021
- Full Text
- View/download PDF
28. 330 WEEK 48 RESULTS OF A PHASE 3 RANDOMIZED CONTROLLED TRIAL OF BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE (B/F/TAF) VS DOLUTEGRAVIR + EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE (DTG+F/TDF) IN ART-NAIVE, HIV/HBV-COINFECTED ADULTS (ALLIANCE)
- Author
-
Avihingsanon, Anchalee, Lu, Hongzhou, Leong, Chee Loon, Hung, Chien-Ching, Koenig, Ellen, Kiertiburanakul, Sasisopin, Lee, Man-Po, Supparatpinyo, Khuanchai, Rahman, Sophia, Brogan, Michelle D'Antoni, Wang, Hongyuan, Hindman, Jason, Martin, Hal, Mehta, Swarup S., Baeten, Jared, and Zhang, Fujie
- Published
- 2023
- Full Text
- View/download PDF
29. Early mortality after late initiation of antiretroviral therapy in the TREAT Asia HIV Observational Database of IeDEA Asia-Pacific
- Author
-
Rupasinghe, Dhanushi, Kiertiburanakul, Sasisopin, Kamarulzaman, Adeeba, Zhang, Fujie, Kumarasamy, Nagalingeswaran, Chaiwarith, Romanee, Merati, Tuti Parwati, Duy, Cuong Do, Khusuwan, Suwimon, Avihingsanon, Anchalee, Lee, Man Po, Ly, Penh Sun, Yunihastuti, Evy, Nguyen, Van Kinh, Ditangco, Rossana, Chan, Yu-Jian, Pujari, Sanjay, Ng, Oon Tek, Choi, Jun Yong, Sim, Benedict Lim Heng, Tanuma, Junko, Sangle, Shashikala, Ross, Jeremy, and Law, Matthew
- Subjects
Adult ,Male ,Anti-HIV Agents ,Cause of Death ,Humans ,Alanine Transaminase ,Female ,HIV Infections ,Mortality ,Poverty ,Article ,CD4 Lymphocyte Count ,Time-to-Treatment - Abstract
Early mortality among those still initiating antiretroviral therapy (ART) with advanced stages of HIV infection in resource-limited settings remains high despite recommendations for universal HIV treatment. We investigated risk factors associated with early mortality in people living with HIV (PLHIV) starting ART at low CD4 levels in the Asia-Pacific.PLHIV enrolled in the Therapeutics, Research, Education and AIDS Training in Asia (TREAT Asia) HIV Observational Database (TAHOD) who initiated ART with a CD4 count 100 cells/μL between 2003 and 2018 were included in the study. Early mortality was defined as death within 1 year of ART initiation. PLHIV in follow-up for1 year were censored at 12 months. Competing risk regression was used to analyse risk factors with loss to follow-up as a competing risk.A total of 1813 PLHIV were included in the study, of whom 74% were male. With 73 (4%) deaths, the overall first-year mortality rate was 4.27 per 100 person-years (PY). Thirty-eight deaths (52%) were AIDS-related, 10 (14%) were immune reconstituted inflammatory syndrome (IRIS)-related, 13 (18%) were non-AIDS-related and 12 (16%) had an unknown cause. Risk factors included having a body mass index (BMI) 18.5 [sub-hazard ratio (SHR) 2.91; 95% confidence interval (CI) 1.60-5.32] compared to BMI 18.5-24.9, and alanine aminotransferase (ALT) ≥ 5 times its upper limit of normal (ULN) (SHR 6.14; 95% CI 1.62-23.20) compared to ALT 5 times its ULN. A higher CD4 count (51-100 cells/μL: SHR 0.28; 95% CI 0.14-0.55; and 100 cells/μL: SHR 0.12; 95% CI 0.05-0.26) was associated with reduced hazard for mortality compared to CD4 count ≤ 25 cells/μL.Fifty-two per cent of early deaths were AIDS-related. Efforts to initiate ART at CD4 counts50 cell/μL are associated with improved short-term survival rates, even in those with late stages of HIV disease.
- Published
- 2019
30. Incidence of syphilis seroconversion among HIV-infected persons in Asia: results from the TREAT Asia HIV observational database
- Author
-
Ahn, Jin Young, Boettiger, David, Kiertiburanakul, Sasisopin, Merati, Tuti Parwati, Huy, Bui Vu, Wong, Wing Wai, Ditangco, Rossana, Lee, Man Po, Oka, Shinichi, Durier, Nicolas, and Choi, Jun Yong
- Subjects
HIV infections -- Complications and side effects -- Research ,Syphilis -- Analysis -- Risk factors ,Health - Abstract
Introduction: Outbreaks of syphilis have been described among HIV-infected men who have sex with men (MSM) in Western communities, whereas reports in Asian countries are limited. We aimed to characterize the incidence and temporal trends of syphilis among HIV-infected MSM compared with HIV-infected non-MSM in Asian countries. Methods: Patients enrolled in the TREAT Asia HIV Observational Database cohort and with a negative non-treponemal test since enrolment were analyzed. Incidence of syphilis seroconversion, defined as a positive non-treponemal test after previously testing negative, was evaluated among patients at sites performing non-treponemal tests at least annually. Factors associated with syphilis seroconversion were investigated at sites doing non-treponemal testing in all new patients and subsequently testing routinely or when patients were suspected of having syphilis. Results: We included 1010 patients from five sites that performed non-treponemal tests in all new patients; those included had negative non-treponemal test results during enrolment and subsequent follow-ups. Among them, 657 patients were from three sites conducting regular non-treponemal testing. The incidence of syphilis seroconversion was 5.38/100 person-years (PY). Incidence was higher in MSM than non-MSM (7.64/100 PY vs. 2.44/100 PY, p Conclusions: We observed a higher incidence of syphilis seroconversion among HIV-infected MSM and a trend to increasing annual incidence. Regular screening for syphilis and targeted interventions to limit transmission are needed in this population. Keywords: syphilis; incidence; seroconversion; HIV; MSM., Introduction After the development of penicillin, the number of syphilis cases fell to its lowest level in 2000 in the United States, from 20.3 cases per 100,000 people to 2.9 [...]
- Published
- 2016
- Full Text
- View/download PDF
31. Validation of the D:A:D Chronic Kidney Disease Risk Score Model Among People Living With HIV in the Asia-Pacific
- Author
-
Han, Win Min, primary, Bijker, Rimke, additional, Chandrasekaran, Ezhilarasi, additional, Pujari, Sanjay, additional, Ng, Oon Tek, additional, Ly, Penh Sun, additional, Lee, Man-Po, additional, Van Nguyen, Kinh, additional, Chan, Yu-Jiun, additional, Do, Cuong Duy, additional, Choi, Jun Yong, additional, Chaiwarith, Romanee, additional, Merati, Tuti Parwati, additional, Kiertiburanakul, Sasisopin, additional, Azwa, Iskandar, additional, Khusuwan, Suwimon, additional, Zhang, Fujie, additional, Gani, Yasmin Mohamed, additional, Tanuma, Junko, additional, Sangle, Shashikala, additional, Ditangco, Rossana, additional, Yunihastuti, Evy, additional, Ross, Jeremy, additional, and Avihingsanon, Anchalee, additional
- Published
- 2020
- Full Text
- View/download PDF
32. Patterns and prognosis of holding regimens for people living with HIV in Asian countries.
- Author
-
Kim, Jung Ho, Jiamsakul, Awachana, Kiertiburanakul, Sasisopin, Huy, Bui Vu, Khusuwan, Suwimon, Kumarasamy, Nagalingeswaran, Ng, Oon Tek, Ly, Penh Sun, Lee, Man-Po, Chan, Yu-Jiun, Gani, Yasmin Mohamed, Azwa, Iskandar, Avihingsanon, Anchalee, Merati, Tuti Parwati, Pujari, Sanjay, Chaiwarith, Romanee, Zhang, Fujie, Tanuma, Junko, Do, Cuong Duy, and Ditangco, Rossana
- Subjects
RALTEGRAVIR ,EFAVIRENZ ,HIV-positive persons ,NON-nucleoside reverse transcriptase inhibitors ,GRAY codes ,INTEGRASE inhibitors - Abstract
The use of holding regimens for people living with HIV (PLWH) without effective antiretroviral options can have effects on outcomes and future treatment options. We aimed to investigate the use of holding regimens for PLWH in Asian countries. Data from adults enrolled in routine HIV care in IeDEA Asia-Pacific cohorts were included. Individuals were considered to be on holding regimen if they had been on combination antiretroviral therapy for at least 6 months, had two confirmed viral loads (VL) ≥1000 copies/mL, and had remained on the same medications for at least 6 months. Survival time was analyzed using Fine and Gray's competing risk regression. Factors associated with CD4 changes and VL <1000 copies/mL were analyzed using linear regression and logistic regression, respectively. A total of 425 PLWH (72.9% male; 45.2% high-income and 54.8% low-to-middle-income country) met criteria for being on a holding regimen. From high-income countries, 63.0% were on protease inhibitors (PIs); from low-to-middle-income countries, 58.4% were on non-nucleoside reverse transcriptase inhibitors (NNRTIs); overall, 4.5% were on integrase inhibitors. The combination of lamivudine, zidovudine, and efavirenz was the most commonly used single regimen (n = 46, 10.8%), followed by lamivudine, zidovudine, and nevirapine (n = 37, 8.7%). Forty-one PLWH (9.7%) died during follow-up (mortality rate 2.0 per 100 person-years). Age >50 years compared to age 31–40 years (sub-hazard ratio [SHR] 3.29, 95% CI 1.45–7.43, p = 0.004), and VL ≥1000 copies/ml compared to VL <1000 copies/mL (SHR, 2.14, 95% CI 1.08–4.25, p = 0.029) were associated with increased mortality, while higher CD4 counts were protective. In our Asia regional cohort, there was a diversity of holding regimens, and the patterns of PI vs. NNRTI use differed by country income levels. Considering the high mortality rate of PLWH with holding regimen, efforts to extend accessibility to additional antiretroviral options are needed in our region. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
33. Weight changes, metabolic syndrome and all‐cause mortality among Asian adults living with HIV.
- Author
-
Han, Win Min, Law, Matthew G., Choi, Jun Yong, Ditangco, Rossana, Kumarasamy, Nagalingeswaran, Chaiwarith, Romanee, Ly, Penh Sun, Khusuwan, Suwimon, Merati, Tuti Parwati, Do, Cuong Duy, Yunihastuti, Evy, Azwa, Iskandar, Lee, Man‐Po, Pham, Thach Ngoc, Chan, Yu‐Jiun, Kiertiburanakul, Sasisopin, Ng, Oon Tek, Tanuma, Junko, Pujari, Sanjay, and Zhang, Fujie
- Subjects
METABOLIC syndrome risk factors ,CAUSES of death ,HIV infections ,HIV-positive persons ,BODY weight ,CONFIDENCE intervals ,ANTIRETROVIRAL agents ,RNA ,DESCRIPTIVE statistics ,BODY mass index ,PROPORTIONAL hazards models - Abstract
Objectives: We investigated weight changes following antiretroviral therapy (ART) initiation, the development of metabolic syndrome (MetS) and its association with all‐cause mortality among Asian adults living with HIV. Methods: Participants enrolled in a regional Asian HIV‐infected cohort with weight and height measurements at ART initiation were eligible for inclusion in the analysis. Factors associated with weight changes and incident MetS (according to the International Diabetic Federation (IDF) definition) were analysed using linear mixed models and Cox regression, respectively. Competing‐risk regression models were used to investigate the association of MetS with all‐cause mortality. Results: Among 4931 people living with HIV (PLWH), 66% were male. At ART initiation, the median age was 34 [interquartile range (IQR) 29–41] years, and the median (IQR) weight and body mass index (BMI) were 55 (48–63) kg and 20.5 (18.4–22.9) kg/m2, respectively. At 1, 2 and 3 years of ART, overall mean (± standard deviation) weight gain was 2.2 (±5.3), 3.0 (±6.2) and 3.7 (±6.5) kg, respectively. Participants with baseline CD4 count ≤ 200 cells/µL [weight difference (diff) = 2.2 kg; 95% confidence interval (CI) 1.9–2.5 kg] and baseline HIV RNA ≥ 100 000 HIV‐1 RNA copies/mL (diff = 0.6 kg; 95% CI 0.2–1.0 kg), and those starting with integrase strand transfer inhibitor (INSTI)‐based ART (diff = 2.1 kg; 95% CI 0.7–3.5 kg vs. nonnucleoside reverse transcriptase inhibitors) had greater weight gain. After exclusion of those with abnormal baseline levels of MetS components, 295/3503 had incident MetS [1.18 (95% CI 1.05–1.32)/100 person‐years (PY)]. The mortality rate was 0.7 (95% CI 0.6–0.8)/100 PY. MetS was not significantly associated with all‐cause mortality in the adjusted model (P = 0.236). Conclusions: Weight gain after ART initiation was significantly higher among those initiating ART with lower CD4 count, higher HIV RNA and an INSTI‐based regimen after controlling for baseline BMI. Greater efforts to identify and manage MetS among PLWH are needed. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
34. Prevalence of oral mucosal lesions in adults undergoing highly active antiretroviral therapy in Hong Kong
- Author
-
Perera, Mahendra, Tsang, Peter Chiu Shun, Samaranayake, Lakshman, Lee, Man Po, and Li, Patrick
- Published
- 2012
- Full Text
- View/download PDF
35. The differential impacts of non-locally acquired infections and treatment interventions on heterosexual HIV transmission in Hong Kong
- Author
-
Wong, Ngai Sze, primary, Lee, Man Po, additional, Wong, Ka Hing, additional, Tsang, Owen T. Y., additional, and Lee, Shui Shan, additional
- Published
- 2020
- Full Text
- View/download PDF
36. Incorporation of information diffusion model for enhancing analyses in HIV molecular surveillance
- Author
-
Kwan, Tsz Ho, primary, Wong, Ngai Sze, additional, Lui, Grace Chung Yan, additional, Chan, Kenny Chi Wai, additional, Tsang, Owen Tak Yin, additional, Leung, Wai Shing, additional, Ho, Kai Man, additional, Lee, Man Po, additional, Lam, Wilson, additional, Chan, Sze Nga, additional, Chan, Denise Pui Chung, additional, and Lee, Shui Shan, additional
- Published
- 2020
- Full Text
- View/download PDF
37. HIV transmission links between past and newly diagnosed infections: a molecular epidemiology study
- Author
-
Kwan, Tsz Ho, primary, Wong, Ngai Sze, additional, Lui, Grace Chung Yan, additional, Chan, Kenny Chi Wai, additional, Tsang, Owen Tak Yin, additional, Leung, Wai Shing, additional, Ho, Kai Man, additional, Lee, Man Po, additional, Lam, Wilson, additional, Chan, Sze Nga, additional, Chan, Denise Pui Chung, additional, To, Sabrina Wai Chi, additional, Yam, Wing Cheong, additional, and Lee, Shui Shan, additional
- Published
- 2019
- Full Text
- View/download PDF
38. Prevalence of chronic kidney disease in Chinese HIV-infected patients
- Author
-
Cheung, Chi Yuen, Wong, Kim Ming, Lee, Man Po, Liu, Yan Lun, Kwok, Heidi, Chung, Rita, Chau, Ka Foon, Li, Chung Ki, and Li, Chun Sang
- Published
- 2007
39. Trends of CD4 cell count levels at the initiation of antiretroviral therapy over time and factors associated with late initiation of antiretroviral therapy among Asian HIV-positive patients
- Author
-
Kiertiburanakul, Sasisopin, Boettiger, David, Lee, Man Po, Omar, Sharifah Fs., Tanuma, Junko, Ng, Oon Tek, Durier, Nicolas, Phanuphak, Praphan, Ditangco, Rossana, Chaiwarith, Romanee, Kantipong, Pacharee, Lee, Christopher Kc., Mustafa, Mahiran, Saphonn, Vonthanak, Ratanasuwan, Winai, Merati, Tuti Parwati, Kumarasamy, Nagalingeswaran, Wong, Wing Wai, Zhang, Fujie, Pham, Thanh Thuy, Pujari, Sanjay, Choi, Jun Yong, Yunihastuti, Evy, and Sungkanuparph, Somnuek
- Subjects
Homosexuality -- Research ,Highly active antiretroviral therapy -- Research -- Health aspects ,Hepatitis C -- Research -- Care and treatment -- Patient outcomes ,Health - Abstract
Introduction: Although antiretroviral therapy (ART) has been rapidly scaled up in Asia, most HIV-positive patients in the region still present with late-stage HIV disease. We aimed to determine trends of pre- ART CD4 levels over time in Asian HIV- positive patients and to determine factors associated with late ART initiation. Methods: Data from two regional cohort observational databases were analyzed for trends in median CD4 cell counts at ART initiation and the proportion of late ART initiation (CD4 cell counts Results: A total of 2737 HIV-positive ART-naive patients from 22 sites in 13 Asian countries and territories were eligible. The overall median (IQR) CD4 cell count at ART initiation was 150 (46-241) cells/[mm.sup.3]. Median CD4 cell counts at ART initiation increased over time, from a low point of 115 cells/[mm.sup.3] in 2008 to a peak of 302 cells/[mm.sup.3] after 2011 (p for trend 0.002). The proportion of patients with late ART initiation significantly decreased over time from 79.1% before 2007 to 36.3% after 2011 (p for trend Conclusions: Median CD4 cell count at ART initiation among Asian patients significantly increases over time but the proportion of patients with late ART initiation is still significant. ART initiation at higher CD4 cell counts remains a challenge. Strategic interventions to increase earlier diagnosis of HIV infection and prompt more rapid linkage to ART must be implemented. Keywords: AIDS; antiretroviral therapy; Asia; CD4; HIV; trends., Introduction Antiretroviral therapy (ART) has dramatically and consistently reduced HIV-associated morbidity and mortality among patients in both developed and developing countries [1-5]. Early initiation of ART, at higher CD4 cell [...]
- Published
- 2014
- Full Text
- View/download PDF
40. Validation of the D:A:D Chronic Kidney Disease Risk Score Model Among People Living With HIV in the Asia-Pacific.
- Author
-
Win Min Han, Bijker, Rimke, Chandrasekaran, Ezhilarasi, Pujari, Sanjay, Oon Tek Ng, Penh Sun Ly, Lee, Man-Po, Kinh Van Nguyen, Yu-Jiun Chan, Cuong Duy Do, Jun Yong Choi, Chaiwarith, Romanee, Merati, Tuti Parwati, Kiertiburanakul, Sasisopin, Azwa, Iskandar, Khusuwan, Suwimon, Fujie Zhang, Gani, Yasmin Mohamed, Junko Tanuma, and Sangle, Shashikala
- Published
- 2020
- Full Text
- View/download PDF
41. Trends in CD4 count response to first-line antiretroviral treatment in HIV-positive patients from Asia, 2003–2013: TAHOD-LITE
- Author
-
De La Mata, Nicole L., Ly, Penh Sun, Ng, Oon Tek, Van Nguyen, Kinh, Merati, Tuti Parwati, Pham, Thuy Thanh, Lee, Man Po, Choi, Jun Yong, Sohn, Annette H., Law, Matthew G., and Kumarasamy, Nagalingeswaran
- Subjects
Adult ,Male ,Asia ,Time Factors ,Anti-HIV Agents ,HIV Infections ,Middle Aged ,Viral Load ,Article ,Drug Administration Schedule ,CD4 Lymphocyte Count ,Antiretroviral Therapy, Highly Active ,Humans ,Female - Abstract
Antiretroviral treatment (ART) guidelines have changed over the past decade, recommending earlier initiation and more tolerable regimens. The study objective was to examine the CD4 response to ART, depending on the year of ART initiation, in HIV-positive patients in the Asia-Pacific. We included HIV-positive adult patients who initiated ART between 2003 and 2013 in our regional cohort from eight urban referral centres in seven countries within Asia. We used mixed-effects linear regression models to evaluate differences in CD4 response by year of ART initiation during 36 months of follow-up, adjusted a priori for other covariates. Overall, 16,962 patients were included. Patients initiating in 2006-9 and 2010-13 had an estimated mean CD4 cell count increase of 8 and 15 cells/µl, respectively, at any given time during the 36-month follow-up, compared to those in 2003-5. The median CD4 cell count at ART initiation also increased from 96 cells/µl in 2003-5 to 173 cells/µl in 2010-13. Our results suggest that the CD4 response to ART is modestly higher for those initiating ART in more recent years. Moreover, fewer patients are presenting with lower absolute CD4 cell counts over time. This is likely to reduce their risk of opportunistic infections and future non-AIDS defining cancers.
- Published
- 2017
42. Changes in renal function with long-term exposure to antiretroviral therapy in HIV-infected adults in Asia
- Author
-
Joshi, Kedar, primary, Boettiger, David, additional, Kerr, Stephen, additional, Nishijima, Takeshi, additional, Van Nguyen, Kinh, additional, Ly, Penh Sun, additional, Lee, Man Po, additional, Kumarasamy, Nagalingeswaran, additional, Wong, Wingwai, additional, Kantipong, Pacharee, additional, Cuong, Do Duy, additional, Kamarulzaman, Adeeba, additional, Choi, Jun Yong, additional, Zhang, Fujie, additional, Chaiwarith, Romanee, additional, Ng, Oon Tek, additional, Kiertiburanakul, Sasisopin, additional, Sim, Benedict Lim Heng, additional, Merati, Tuti Parwati, additional, Yunihastuti, Evy, additional, Ditangco, Rossana, additional, Ross, Jeremy, additional, and Pujari, Sanjay, additional
- Published
- 2018
- Full Text
- View/download PDF
43. Non-AIDS defining malignancies among HIV-infected patients in a tertiary referral center in Hong Kong.
- Author
-
Mak, Daisy Wing-san, primary, Hui, Eugenie Ka, additional, Chan, Lawrence, additional, Lam, Wilson, additional, Lee, Man Po, additional, and Lau, Sze Man June, additional
- Published
- 2018
- Full Text
- View/download PDF
44. Durability of Antiretroviral Therapy Regimens and Determinants for Change in HIV-1-Infected Patients in the TREAT Asia HIV Observational Database (TAHOD-LITE)
- Author
-
Martinez-Vega, Rosario, primary, De La Mata, Nicole L, additional, Kumarasamy, Nagalingeswaran, additional, Ly, Penh Sun, additional, Van Nguyen, Kinh, additional, Merati, Tuti P, additional, Pham, Thi Thanh, additional, Lee, Man Po, additional, Choi, Jun Yong, additional, Ross, Jeremy L, additional, and Ng, Oon Tek, additional
- Published
- 2018
- Full Text
- View/download PDF
45. Transmission network structure and newly diagnosed HIV infections: a molecular epidemiology study
- Author
-
Kwan, Tsz Ho, primary, Wong, Ngai Sze, additional, Chan, Kenny Chi Wai, additional, Tsang, Owen Tak Yin, additional, Lee, Man Po, additional, Lui, Grace Chung Yan, additional, Chan, Denise Pui Chung, additional, Yam, Wing Cheong, additional, and Lee, Shui Shan, additional
- Published
- 2017
- Full Text
- View/download PDF
46. PREDICTORS OF HEPATITIS B TREATMENT RESPONSE IN PEOPLE WITH HIV/HBV COINFECTION.
- Author
-
Avihingsanon, Anchalee, Leong, Chee L., Chien-Ching Hung, Koenig, Ellen, Lee, Man-Po, Supparatpinyo, Khuanchai, Zhang, Fujie, Wang, Hongyuan, Martin, Hal, Hindman, Jason, Baeten, Jared M., and Kiertiburanakul, Sasisopin
- Published
- 2023
47. Treatment Modification after Second-Line Failure among People Living with HIV in Asia-Pacific
- Author
-
Jiamsakul, Awachana, Azwa, Iskandar, Zhang, Fujie, Yunihastuti, Evy, Ditangco, Rossana, Kumarasamy, Nagalingeswaran, Ng, Oon Tek, Chan, Yu-Jiun, Ly, Penh Sun, Choi, Jun Yong, Lee, Man-Po, Pujari, Sanjay, Kiertiburanakul, Sasisopin, Chaiwarith, Romanee, Merati, Tuti Parwati, Sangle, Shashikala, Khusuwan, Suwimon, Sim, Benedict LH, Avihingsanon, Anchalee, Do, Cuong Duy, Tanuma, Junko, Ross, Jeremy, and Law, Matthew
- Abstract
Background The World Health Organization recommends continuation with the failing second-line regimen if third-line option is not available. We investigated treatment outcomes among people living with HIV in Asia who continued with failing second-line regimens compared with those who had treatment modifications after failure.Methods Treatment modification was defined as a change of two antiretrovirals, a drug class change or treatment interruption (TI), all for >14 days. We assessed factors associated with CD4 changes and undetectable viral load (UVL <1,000 copies/ml) at 1 year after second-line failure using linear and logistic regression, respectively. Survival time was analysed using competing risk regression.Results Of the 328 patients who failed second-line ART in our cohorts, 208 (63%) had a subsequent treatment modification. Compared with those who continued the failing regimen, the average CD4 cell increase was higher in patients who had a modification without TI (difference =77.5, 95% CI 35.3, 119.7) while no difference was observed among those with TI (difference =-5.3, 95% CI -67.3, 56.8). Compared with those who continued the failing regimen, the odds of achieving UVL was lower in patients with TI (OR=0.18, 95% CI 0.06, 0.60) and similar among those who had a modification without TI (OR=1.97, 95% CI 0.95, 4.10), with proportions of UVL 60%, 22% and 75%, respectively. Survival time was not affected by treatment modifications.Conclusions CD4 cell improvements were observed in those who had treatment modification without TI compared with those on the failing regimen. When no other options are available, maintaining the same failing ART combination provided better VL control than interrupting treatment.
- Published
- 2020
- Full Text
- View/download PDF
48. Cardiovascular Disease and Cardiovascular Disease Risk in HIV-Positive Populations in the Asian Region
- Author
-
Bijker, Rimke, primary, Choi, Jun Yong, additional, Ditangco, Rossana, additional, Kiertiburanakul, Sasisopin, additional, Lee, Man Po, additional, Siwamogsatham, Sarawut, additional, Pujari, Sanjay, additional, Ross, Jeremy, additional, Wong, Chi-yuen, additional, Wong, Wing-Wai, additional, Yunihastuti, Evy, additional, and Law, Matthew, additional
- Published
- 2017
- Full Text
- View/download PDF
49. HIV and Aging: Demographic Change in the Asia-Pacific Region
- Author
-
Puhr, Rainer, primary, Kumarasamy, Nagalingeswaran, additional, Ly, Penh Sun, additional, Ng, Oon Tek, additional, Van Nguyen, Kinh, additional, Merati, Tuti Parwati, additional, Pham, Thuy Thanh, additional, Lee, Man Po, additional, Choi, Jun Yong, additional, Ross, Jeremy L., additional, and Law, Matthew G., additional
- Published
- 2017
- Full Text
- View/download PDF
50. Growing challenges for HIV programmes in Asia: clinic population trends, 2003–2013
- Author
-
De La Mata, Nicole L., primary, Kumarasamy, Nagalingeswaran, additional, Ly, Penh Sun, additional, Ng, Oon Tek, additional, Nguyen, Kinh Van, additional, Merati, Tuti Parwati, additional, Lee, Man Po, additional, Do, Cuong Duy, additional, Choi, Jun Yong, additional, Ross, Jeremy L., additional, and Law, Matthew G., additional
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.